Conclusion
NSCLC, treatment‐naive
LUNG CANCER, ONCOLOGY, NSCLC
Nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer OS vs. the placebo combination. We believe this regimen is viable as a standard, first‐line treatment for patients with advanced nsNSCLC without driver mutations in The ONO‐4538‐52/TASUKI‐52 study investigated the efficacy and safety of nivolumab versus placebo, both combined with platinum chemotherapy and bevacizumab, as first‐line treatment for advanced non‐squamous non‐small cell lung cancer (NSCLC). After a minimum follow‐up of 19.4 months, overall survival significantly favored the nivolumab arm, and this survival benefit was observed regardless of programmed death‐ligand 1 expression level. These results indicate that nivolumab plus platinum chemotherapy and bevacizumab is an effective option for treatment‐naive patients with advanced non‐squamous NSCLC without driver mutations.
Data reported in this manuscript were submitted as an abstract to the 2022 Annual Meeting of the Japanese Society of Medical Oncology. Interim results were published as Sugawara et al.Study registration numbers: 